

PTO/SB/08A (08-00)

Approved for use through 10/31/2002 OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for Form 1449/A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	09/545,139
		Filing Date	April 7, 2000
		First Named Inventor	Robert J. D'Amato
		Group Art Unit	1614
		Examiner Name	Goldberg, J.
Sheet 2	of 2	Attorney Docket Number 05213-0650 (43170-219681)	

OTHER INFORMATION - NON PATENT LITERATURE DOCUMENTS			
Examiner Initials	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T ²
	2	KOCH, H. "The Arene Oxide Hypothesis of Thalidomide Action. Considerations On The Molecular Mechanism of Action of The 'Classical' Teratogen." <u>Sci. Pharm.</u> 49. pgs. 67-99 (1981).	

Examiner Signature		Date Considered	7/16/02
--------------------	--	-----------------	---------

¹Unique citation designation number. ²Applicant is to place a check mark here if English language translation is attached.

ATLLIB02# 72822.1